5-year outcomes of bictegravir-emtricitabine-tenofovir alafenamide (B-F-TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 cell count in two Phase 3 randomised clinical trials
Authors
Ramgopal, M; Warupa, A; Baumgarten, A; Berhe, M; Pozniak, A; Orkin, C; Tiraboschi, JM; Hagins, D; Huang, H; Andreatta, KCollections
- Centre for Immunobiology [1101]